Clinical Trial Update: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update assessing the long-term safety and efficacy of Lebrikizumab (LY3650150) in participants aged 6 months to under 18 years with moder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis, Eczema | Phase 3 | Status: ENROLLING_BY_INVITATION